JP Patent
JP6665154B2 — 置換尿素誘導体及びその薬学的使用
Assigned to ノース・アンド・サウス・ブラザー・ファーマシー・インベストメント・カンパニー・リミテッド · Expires 2020-03-13 · 6y expired
What this patent protects
Patent listed against Retevmo.
Drugs covered by this patent
- Retevmo (SELPERCATINIB) · Eli Lilly
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.